NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today anno
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sal
AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population   AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in
REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger wit
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Defin
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it wi
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology asset to Ayala's portfolio with data anticipated in the first half of 2024 REHOVOT and TEL AVIV, Isra
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ® (p
SuperCom Ltd. (NASDAQ:SPCB) with the stream of 1.39% also noticed, India Advaxis, Inc. (NASDAQ:ADXS) encountered a rapid change of 9.71% in the last hour of Thursday’s trading session. SuperCom Ltd. … The post Stock on the Move: SuperCom Ltd. (NASDAQ:SPCB), Advaxis, Inc. (NASDAQ:ADXS) appeared first on Stocks Equity .
Advaxis, Inc. (NASDAQ:ADXS) with the stream of -17.43% also noticed, India Indonesia Energy Corporation Limited (AMEX:INDO) encountered a rapid change of 50.85% in the last hour of Monday’s trading session. … The post Hooky Stock: Advaxis, Inc. (NASDAQ:ADXS), Indonesia Energy Corporation Limited (AMEX:INDO) appeared first on Stocks Equity .
Advaxis, Inc. (NASDAQ:ADXS) with the stream of 4.45% also noticed, India Gold Standard Ventures Corp (AMEX:GSV) encountered a rapid change of 4.07% in the last hour of trading session. Advaxis, … The post Remarkable Stock Buzz: Advaxis, Inc. (NASDAQ:ADXS), Gold Standard Ventures Corp (AMEX:GSV) appeared first on Stocks Equity .

Bright Stock Buzz: Advaxis, Inc. (NASDAQ:ADXS), BEST Inc. (NYSE:BEST)

03:17am, Wednesday, 23'rd Feb 2022 Stock Equity
Advaxis, Inc. (NASDAQ:ADXS) with the stream of 1.14% also noticed, India BEST Inc. (NYSE:BEST) encountered a rapid change of -18.64% in the last hour of Tuesdays trading session. Advaxis, Inc. The post Bright Stock Buzz: Advaxis, Inc. (NASDAQ:ADXS), BEST Inc. (NYSE:BEST) appeared first on Stocks Equity .
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE